C4 glomerulopathy natural history

	C4 glomerulopathy Microchapters
Complement Mediated Glomerular Disorders Main Page
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating C4 glomerulopathy from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
X ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Studies
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
C4 glomerulopathy natural history On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of C4 glomerulopathy natural history All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on C4 glomerulopathy natural history
CDC on C4 glomerulopathy natural history
C4 glomerulopathy natural history in the news
Blogs on C4 glomerulopathy natural history
Directions to Hospitals Treating C4 glomerulopathy
Risk calculators and risk factors for C4 glomerulopathy natural history

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Ali Poyan Mehr, M.D. [2]; Associate Editor(s)-in-Chief: Olufunmilola Olubukola M.D.[3]

Overview

If left untreated, C4 glomerulopathy may progress to develop renal failure.

Natural History, Complications, and Prognosis

Natural History

The symptoms of C4 glomerulopathy usually start with symptoms such as proteinuria, hematuria, edema, renal insufficiency hypocomplementemia, and hypertension^[1].

Complications

Common complications of C4 glomerulopathy include^[2]:

Renal failure

Prognosis

Depending on the extent of the disease at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor.

References

↑ Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, Kirschfink M; et al. (2005). "Membranoproliferative glomerulonephritis type II (dense deposit disease): an update". J Am Soc Nephrol. 16 (5): 1392–403. doi:10.1681/ASN.2005010078. PMID 15800116.
↑ Garam N, Prohászka Z, Szilágyi Á, Aigner C, Schmidt A, Gaggl M; et al. (2019). "C4 nephritic factor in patients with immune-complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy". Orphanet J Rare Dis. 14 (1): 247. doi:10.1186/s13023-019-1237-8. PMC 6839100 Check |pmc= value (help). PMID 31703608.

Template:WH Template:WS

[pmid15800116-1] Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, Kirschfink M; et al. (2005). "Membranoproliferative glomerulonephritis type II (dense deposit disease): an update". J Am Soc Nephrol. 16 (5): 1392–403. doi:10.1681/ASN.2005010078. PMID 15800116.

[pmid31703608-2] Garam N, Prohászka Z, Szilágyi Á, Aigner C, Schmidt A, Gaggl M; et al. (2019). "C4 nephritic factor in patients with immune-complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy". Orphanet J Rare Dis. 14 (1): 247. doi:10.1186/s13023-019-1237-8. PMC 6839100 Check |pmc= value (help). PMID 31703608.

[1]

[2]